SEC Form 4 · accession 0001140361-17-042821
SYNERGY PHARMACEUTICALS, INC. · SGYP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
PAULSON & CO. INC.
10% Owner
Period of report
Nov 10, 2017
Accepted (ET)
Nov 14, 2017 · 4:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001347613
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, par value of $.0001F1,F2 | Nov 10, 2017 | S | 8,750,000 | $2.8204 | D | 15,312,368 | I | By Managed Funds and Accounts |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Paulson & Co. Inc. ("Paulson") is an investment advisor registered under the Investment Advisors Act of 1940. Paulson is the investment manager of investment funds (the "Funds") and certain separately managed accounts (the "Separately Managed Accounts"). John Paulson is the controlling person of Paulson. All securities reported on this Form 4 are owned by the Funds or held in the Separately Managed Accounts.
- F2Each of Paulson and John Paulson may be deemed to indirectly beneficially own the securities directly owned by the Funds or held in the Separately Managed Accounts. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Act"), the filing of this Form 4 shall not be deemed an admission by any person reporting on this Form 4 that such person, for purposes of Section 16 of the Act or otherwise, is the beneficial owner of any equity securities covered by this Form 4.